Clinical Trial

The Effect of Glioblastoma PSMA Expression Following Tumour VEGF Blockade From Bevacizumab

Study acronym: GUAVA
Recruiting
View on ClinicalTrials.gov →
Summary
This trial is a single arm study for patients receiving bevacizumab for IDH-wildtype glioblastoma. Patients receiving bevacizumab (an anti-VEGF therapy) will receive PSMA scans to investigate the role of PSMA expression in glioblastoma and its relationship to VEGF expression.
Protocol Amendment History 1 change
critical Recruitment opened 2026-08-14
Trial Details
NCT Number NCT07052877
Lead Sponsor Royal North Shore Hospital
Conditions Glioblastoma, Glioblastoma Multiforme (GBM)
Enrollment 20 participants
Start Date 2025-12-11
Primary Completion 2027-07 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2026-08-13